3+ day, 4+ hour ago   (562+ words) Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), just a year after it was cleared as a second-line option. Hyrnuo (sevabertinib) has been cleared for earlier use…...

4+ day, 1+ hour ago   (427+ words) Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), after delivering as a dual regimen with AstraZeneca's Imfinzi in the DeLLphi-305 study. The trial compared the combination as a first-line maintenance therapy…...

4+ day, 3+ hour ago   (616+ words) The FDA has started a priority review of AstraZeneca's IL-33-targeting antibody tozorakimab for chronic obstructive pulmonary disease (COPD), setting up a decision on the would-be blockbuster in the first quarter of 2027. It's an indicator of AZ's excitement about tozorakimab that…...

5+ day, 2+ hour ago   (563+ words) Aerial view of Sandoz' drug substance facility in Lendava, Slovenia, part of a $1bn European hub for biosimilar development and production. Sandoz has told investors that it intends to double its net sales between 2025 and 2035, and sees a pivot towards biosimilars…...

5+ day, 1+ hour ago   (552+ words) Swiss biotech Pharvaris has reported positive data from a phase 3 trial of its drug for hereditary angioedema (HAE), setting up marketing applications next year. The drug – an extended-release formulation of bradykinin B2 receptor antagonist deucrictibant – achieved an 83% reduction compared to placebo…...

5+ day, 4+ hour ago   (809+ words) Drug development is an inherently risky endeavour, with the average probability of approval for a drug entering Phase I studies now sitting at just 6.7%. While much of this can be attributed to lack of efficacy, factors such as poor clinical…...

5+ day, 5+ hour ago   (592+ words) ABPI chief executive Richard Torbett. The UK is starting to benefit from a "real partnership" between the pharma industry and government that is reversing years of diminishing investment, but more must be done to secure the gains. That's the conclusion…...

6+ day, 1+ hour ago   (508+ words) London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575 million ($668 million), which will be used to "back Europe's boldest innovators." The new fund – which has overshot its expected tally of €500 million – is earmarked for companies operating…...

6+ day, 1+ hour ago   (159+ words) The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease. The meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets,…...

6+ day, 2+ hour ago   (399+ words) Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after an interim look at the data suggested they would be unlikely to show a positive result. The revelation – first reported by Endpoints – affects the…...